About this trial
This randomized controlled trial will investigate the effects of a 6-week polarized aerobic training intervention on vascular and cardiorespiratory function in apparently healthy sedentary adults aged 30-50 years. Polarized training is characterized by a high proportion of low-intensity aerobic exercise combined with a smaller volume of high-intensity interval exercise, potentially providing complementary haemodynamic and physiological stimuli that support vascular adaptations and cardiovascular health. Although polarized training has been extensively studied in athletic populations, its effects on vascular function in sedentary adults remain insufficiently understood.
Thirty participants will be randomly assigned in a 1:1 ratio to either a supervised polarized aerobic training group or a non-exercising control group. The intervention will consist of a 6-week supervised cycle ergometer training program performed three times per week and prescribed according to individual ventilatory thresholds obtained during cardiopulmonary exercise testing. Training sessions will combine low-to-moderate-intensity continuous exercise and high-intensity interval exercise. Participants allocated to the control group will maintain their habitual sedentary lifestyle throughout the study period.
The primary outcome will be endothelial function assessed by brachial artery flow-mediated dilation. Secondary outcomes will include arterial stiffness assessed by pulse wave velocity, central haemodynamics, microvascular function, cardiorespiratory fitness, skeletal muscle function, pulmonary function, respiratory muscle strength, and circulating biomarkers related to vascular health. Outcome measures will be assessed at baseline and after completion of the 6-week intervention period. The findings of this study may improve understanding of vascular and systemic adaptations to polarized aerobic training and help inform future exercise-based strategies for cardiovascular risk reduction in apparently healthy sedentary adults.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Men and women aged 30-50 years
Apparently healthy individuals without diagnosed cardiovascular, metabolic, or renal disease
Sedentary lifestyle verified using the Global Physical Activity Questionnaire (GPAQ) and current physical activity classification criteria
Ambulatory blood pressure values within the normotensive range (<140 mmHg systolic and <90 mmHg diastolic)
Disqualifiers
Ambulatory blood pressure values ≥140 mmHg systolic and/or ≥90 mmHg diastolic
Moderate or high physical activity level according to the Global Physical Activity Questionnaire (GPAQ)
Diagnosed chronic cardiovascular, metabolic, renal, respiratory, or other systemic disease
Use of prescribed medication influencing cardiovascular or metabolic function
Trial design
Parallel
Treatments tested in this trial
Polarized Aerobic Training
BehavioralParticipants will undergo a 6-week supervised polarized aerobic training programme performed three times weekly on a cycle ergometer. The intervention will combine low-to-moderate-intensity continuous training and high-intensity interval training prescribed according to individual ventilatory thresholds determined during cardiopulmonary exercise testing. The weekly structure will include two high-intensity interval sessions and one continuous aerobic training session, thereby creating a polarized intensity distribution characterized by a predominance of low-intensity exercise and limited exposure to the moderate-intensity domain. Exercise intensity will be individualized using heart rate and power output targets, and all sessions will be supervised by trained personnel.
Treatment groups
Trial outcomes
Primary outcomes
Brachial artery flow-mediated dilation (FMD)
Endothelial function will be assessed using brachial artery flow-mediated dilation (FMD) measured by high-resolution ultrasound following a standardized ischemia-reperfusion protocol. FMD will be expressed as the relative (%) increase in brachial artery diameter following cuff release compared with baseline diameter.
Flow-mediated slowing (FMS)
Flow-mediated slowing (FMS, %) will be assessed using pulse wave velocity deceleration after occlusion of the brachial artery with an oscillometric device (Vicorder, Skidmore Medical, United Kingdom).
Carotid-femoral pulse wave velocity
Carotid-femoral pulse wave velocity will be assessed using an oscillometric device (Vicorder, Skidmore Medical, United Kingdom) and reported in m/s.
Brachial-radial pulse wave velocity
Brachial-radial pulse wave velocity will be assessed using an oscillometric device (Vicorder, Skidmore Medical, United Kingdom) and reported in m/s
Secondary outcomes
Aortic pulse pressure (AOPP)
Aortic pulse pressure will be assessed using oscillometric pulse wave analysis (Vicorder, software version 4; Skidmore Medical, United Kingdom) and reported in mmHg.
Augmentation index
Augmentation index will be assessed using oscillometric pulse wave analysis (Vicorder, software version 4; Skidmore Medical, United Kingdom) and reported as a percentage.
Muscle tissue reoxygenation slope (microvascular reactivity)
Muscle tissue reoxygenation following reactive hyperaemia will be assessed using near-infrared spectroscopy during a vascular occlusion-reperfusion protocol. A continuous-wave NIRS system (PortaMon; Artinis Medical Systems, The Netherlands) will be used to record tissue saturation index continuously during baseline, arterial occlusion, and reperfusion. Microvascular reactivity will be quantified as the reoxygenation slope, calculated from the increase in tissue saturation index immediately after cuff release, and reported as percentage points per second (%/s).
Skeletal muscle stiffness
Skeletal muscle stiffness (N/m) will be assessed non-invasively using a handheld myotonometer (MyotonPRO; Myoton AS, Estonia). Measurements will be performed with participants in a relaxed, standardised position to assess passive mechanical properties of the quadriceps femoris muscles.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.